Global
CN
EN
About
Development milestones
Mission&Vision
Founder
Research Achievement
Technology Platforms
Single domain antibody
Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing
Co-Development
Career development
Our Story
Social Recruitment
News
Company News
Media
Contact Us
Company Address
Online Message
×
Home
中文
EN
About
About Novamab
Technology Platforms
PIPELINE
BUSINESS PARTNERSHIPS
Market target layout
Strategic Cooperation
Career development
News
Company News
Media
Contact Us
Our Story
Share the latest information
Our Story
News
Company News
Media
2025-03-25
Novamab Announces Successful Completion of LQ036 Phase IIa Clinical Trial Demonstrating Superior Efficacy and Safety – The World’s First Inhaled IL-4Rα Biologic Offers an Innovative Treatment Option for Asthma Patients
More
2021-03-12
Novamab has completed a round of financing of billion yuan!
More
2021-03-08
Rocky Biology has obtained the high-tech enterprise certificate!
More
2020-12-08
Novamab won two honors!
More
2020-10-16
We will work together and forge ahead - the third anniversary of the founding of Novamab
More
2020-09-17
Novamab won the recognition of high-tech enterprises in Shanghai!
More
2019-11-22
The joint research results of Novamab and Peking University Cancer Hospital in nuclear medicine were published online in the international journal BIOCONJUGATE CHEMISTRY
More
2019-10-16
Publication of research and development results of industrialized new PD-1 nanoantibody drug expressed by Pichia pastoris
More
2019-10-10
Report on the 29th ERS (European Respiratory Society Annual Conference) Conference of Loki Biology
More
2019-07-27
Don't forget your original intention and move forward courageously -- and Loqi 2019 Mid-Year Summary and Commendation Conference
More
2019-04-11
LQ036, the world's first inhaled nano-antibody drug for the treatment of moderate and severe asthma, has completed the administration of the first patient in China's clinical phase I!
More
总计 51
1
2
3
4
5
6